ACCF/AHA 2011 health policy statement on therapeutic interchange and substitution: A report of the american college of cardiology foundation clinical quality committee

Circulation

Volumn 124, Issue 11, 2011, Pages 1290-1310

  Holmes, David R ^a   Becker, Jeffrey A ^a   Granger, Christopher B ^a   Limacher, Marian C ^a   Page, Robert Lee ^a   Sila, Cathy ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; ATORVASTATIN; BISOPROLOL; BUCINDOLOL; CARBAMAZEPINE; CARVEDILOL; CLOPIDOGREL; CYCLOSPORIN; ENOXAPARIN; ETHINYLESTRADIOL; EVEROLIMUS; GENERIC DRUG; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; LEVOTHYROXINE; LITHIUM; METOPROLOL; METOPROLOL SUCCINATE; OXCARBAZEPINE; PHENYTOIN; PRASUGREL; QUINIDINE; RAPAMYCIN; SUCCIMER DIMETHYL ESTER; SUCCINIC ACID; TACROLIMUS; TICAGRELOR; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL; WARFARIN;

ACUTE CORONARY SYNDROME; ARTICLE; BIOEQUIVALENCE; DOCUMENTATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SUBSTITUTION; FOOD AND DRUG ADMINISTRATION; HEALTH CARE; HEALTH CARE POLICY; HEART FAILURE; HUMAN; HYPERTENSION; MEDICAL SOCIETY; MYALGIA; PATENT; PEER REVIEW; PHARMACOGENOMICS; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

AMERICAN HEART ASSOCIATION; CARDIOLOGY; DRUG SUBSTITUTION; FOUNDATIONS; HEALTH POLICY; HUMANS; RESEARCH REPORT; SOCIETIES, MEDICAL; UNITED STATES;

EID: 80052808963     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIR.0b013e31822d97d5     Document Type: Article

References (99)

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products With Therapeutic Equivalence Evaluations. 2011. Available at: http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm. Accessed February 6, 2011.
2. Drug Price Competition and Patent Term Restoration Act of 1984. Public Law 98-417 (S 1538).
3. Chen ML, Straughn AB, Sadrieh N, et al. A modern view of excipient effects on bioequivalence: case study of sorbitol. Pharm Res. 2007;24: 73-80. (Pubitemid 44902572)
4. Dannenfelser RM, He H, Joshi Y, et al. Development of clinical dosage forms for a poorly water soluble drug I: application of polyethylene glycol-polysorbate 80 solid dispersion carrier system. J Pharm Sci. 2004; 93:1165-75. (Pubitemid 38529690)
5. Jackson K, Young D, Pant S. Drug-excipient interactions and their affect on absorption. Pharm Sci Technolo Today. 2000;3:336-45.
6. Davit BM, Nwakama PE, Buehler GJ, et al. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother. 2009; 43:1583-97.
7. Chen ML, Shah V, Patnaik R, et al. Bioavailability and bioequivalence: an FDA regulatory overview. Pharm Res. 2001;18:1645-50. (Pubitemid 34020417)
8. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products-general considerations. 2003. Available at: http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/ Guidances/UCM070124.pdf. Accessed February 6, 2011.
9. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987;15:657-80.
10. Tam SW, Sabolinski ML, Worcel M, et al. Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox. Clin Pharmacokinet. 2007;46:885-95. (Pubitemid 47443312)
11. Buehler GJ. History of Bioequivalence for Critical Dose Drugs. 2010. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/AdvisoryCommitteeforPharmace uticalScienceandClinicalPharmacology/UCM209319.pdf. Accessed February 6, 2011.
12. Summary minutes of the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology. 2010. Available at: http://www.fda. gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ AdvisoryCommitteeforPharmaceuticalScienceandClinicalPharmacology/UCM210930.pdf. Accessed February 6, 2011.
13. Holmes DR Jr, Dehmer GJ, Kaul S, et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation. 2010;122:537-57.
14. Ledford H. 'Biosimilar' drugs poised to penetrate market. Nature. 2010; 468:18-9.
15. U.S. Food and Drug Administration Department of Health and Human Services. Food and drugs. Ch.1, subch. F, Biologics. Fed Regist. 2010.
16. Giezen TJ, Mantel-Teeuwisse AK, Straus SM, et al. Safety-related regulatory actions for biologicals approved in the United States and the European Union. JAMA. 2008;300:1887-96.
17. Lacana E, Amur S, Mummanneni P, et al. The emerging role of pharmacogenomics in biologics. Clin Pharmacol Ther. 2007;82:466-71. (Pubitemid 47414357)
18. Frank RG. Regulation of follow-on biologics. N Engl J Med. 2007;357: 841-3. (Pubitemid 47347316)
19. Hennessy S, Leonard CE, Platt R. Assessing the safety and comparative effectiveness of follow-on biologics (biosimilars) in the United States. Clin Pharmacol Ther. 2010;87:157-9.
20. Public Health Service Act, USC 42. U.S. Food and Drug Administration. 2009.
21. U.S. Food and Drug Administration. Approval pathway for biosimilar and interchangeable biological products; public hearing; request for comments. Fed Regist. 2010;75:61497-501.
22. Kalodiki E, Fareed J. New and generic anticoagulants and biosimilars: safety considerations. Clin Appl Thromb Hemost. 2011;17:136-9.
23. Roden DM, Altman RB, Benowitz NL, et al. Pharmacogenomics: challenges and opportunities. Ann Intern Med. 2006;145:749-57. (Pubitemid 351650355)
24. Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med. 2008; 358:999-1008. (Pubitemid 351347099)
25. Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360:753-64.
26. Matcher DB, Thakur ME, Grossman I, et al. Testing for Cytochrome P450 Polymorphisms in Adults With Non-Psychotic Depression Treated With Selective Serotonin Reuptake Inhibitors (SSRIs). (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-02-0025). Rockville, Md: Agency for Healthcare Research and Quality; 2007. AHRQ Publication No. 07-E002 ed.
27. Langaee TY, Gong Y, Yarandi HN, et al. Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil. Clin Pharmacol Ther. 2007;81:386-91. (Pubitemid 46364490)
28. Niu Y, Gong Y, Langaee TY, et al. Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES). Circ Cardiovasc Genet. 2010;3:548-55.
29. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-7.
30. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362:7-13. (Pubitemid 36835815)
31. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659-67.
32. Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail. 2010;16:e1-194.
33. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci USA. 2006;103:11288-93. (Pubitemid 44156511)
34. White HL, de Boer RA, Maqbool A, et al. An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF substudy. Eur J Heart Fail. 2003;5:463-8. (Pubitemid 37021640)
35. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354-62.
36. Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302:849-57.
37. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009;119: 2553-60.
38. Tantry US, Bliden KP, Wei C, et al. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Circ Cardiovasc Genet. 2010;3:556-66.
39. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med. 2008;359:789-99.
40. Nakamura Y. Pharmacogenomics and drug toxicity. N Engl J Med. 2008;359:856-8.
41. Pereira NL, Weinshilboum RM. Cardiovascular pharmacogenomics and individualized drug therapy. Nat Rev Cardiol. 2009;6:632-8.
42. Brushwood DB. Legal issues surrounding therapeutic interchange in institutional settings: an update. Formulary. 2001;36:796-804. (Pubitemid 33089871)
43. Congressional Budget Office. Effects of using generic drugs on Medicare's prescription drug spending. Washington, DC: Congressional Budget Office; 2010. Publication No. 4043.
44. Assistant Secretary for Planning and Evaluation Staff. ASPE issue brief: expanding the use of generic drugs. Washington, DC: U.S. Department of Health and Human Services, 2010.
45. Generic Drugs: A Law CE. Pharmacist's Letter. Course No. 36. 2006. Available at: http://pharmacistsletter.therapeuticresearch.com/ce/ceCourse. aspx?pc-06-36. Accessed June 22, 2011.
46. Crowther B, Munoz M. The skinny on narrow therapeutic index drugs used in transplantation: a brand vs. generic debate. Presented at the University of Texas at Austin College of Pharmacy, January 29, 2010; SanAntonio,TX. Availableat:http://www.utexas.edu/pharmacy/divisions/pharmaco/rounds/01-29-10. pdf. Accessed April 27, 2011.
47. Piepho RW. Therapeutic interchange and equivalence: focus on antihypertensive agents: substitution at the pharmacy level. 2011. Available at: http://www.medscape.org/viewarticle/416390-4. Accessed February 7, 2011.
48. Gray T, Bertch K, Galt K, et al. Guidelines for therapeutic interchange-2004. Pharmacotherapy. 2005;25:1666-80.
49. Academy of Managed Care Pharmacy. Therapeutic interchange. 2003. Available at: http://www.amcp.org/amcp.ark?p-AA46FF1F. Accessed February 6, 2011.
50. American Society of Health System Pharmacy. Principles of a sound drug formulary system. 2006. Available at: http://www.ashp.org/DocLibrary/ BestPractices/FormEndPrinciples.aspx. Accessed February 6, 2011.
51. American Medical Association. Report 2 of the Council on Science and Public Health (A-04): impact of drug formularies and therapeutic interchange on health outcomes. 2004. Available at: http://www.amaassn.org/resources/doc/csaph/ a04csa2-fulltext.pdf. Accessed February 6, 2011.
52. Therapeutic substitution and formulary systems. American College of Physicians. Ann Intern Med. 1990;113:160-3.
53. American Society of Consultant Pharmacists. Guidelines for implementing therapeutic interchange in long-term care. 1997. Available at: http://www.ascp.com/resources/policy/upload/Gui97-Therapeutic% 20Interchange.pdf. Accessed February 6, 2011.
54. Institute of Medicine. Envisioning the National Health Care Quality Report. Washington, DC: National Academy Press; 2001.
55. Oandasan I, D'Amour D, Zwarenstein M, et al. Interdisciplinary education for collaborative, patient-centred practice: research and findings report. February 20, 2004. Ottawa, Canada: Health Canada, 2004.
56. Alloway RR, Isaacs R, Lake K, et al. Report of the American Society of Transplantation conference on immunosuppressive drugs and the use of generic immunosuppressants. Am J Transplant. 2003;3:1211-5. (Pubitemid 37214617)
57. American Medical Association. Report 2 of the Council on Science and Public Health (A-07): generic substitution of narrow therapeutic index drugs. 2007. Available at: http://www.ama-assn.org/resources/doc/csaph/csaph2a07- fulltext.pdf. Accessed February 6, 2011.
58. Sabatini S, Ferguson RM, Helderman JH, et al. Drug substitution in transplantation: a National Kidney Foundation White Paper. Am J Kidney Dis. 1999;33:389-97. (Pubitemid 29072246)
59. Uber PA, Ross HJ, Zuckermann AO, et al. Generic drug immunosuppression in thoracic transplantation: an ISHLT educational advisory. J Heart Lung Transplant. 2009;28:655-60.
60. American Academy of Neurology. Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy. 2006. Available at: http://www.aan.com/globals/axon/assets/2648.pdf. Accessed February 6, 2011.
61. Academy of Managed Care Pharmacy. Narrow therapeutic index (NTI) drugs, interchange of. 2004. Available at: http://www.amcp.org/amcp. ark?p-AA3B226A. Accessed February 6, 2011.
62. Academy of Managed Care Pharmacy. Generic drugs. 2010. Available at: http://www.amcp.org/amcp.ark?p-AA2D6237. Accessed February 6, 2011.
63. American Thyroid Association. AACE, TES and ATA joint position statement on the use and interchangeability of thyroxine products. 2004. Available at: https://www.aace.com/sites/default/files/AACETES-ATAThyroxineProducts. pdf. Accessed February 6, 2011.
64. Generic Pharmaceutical Association. Authorized generics. 2010. Available at: http://www.gphaonline.org/issues/authorized-generics. Accessed February 6, 2011.
65. Wangge G, Klungel OH, Roes KC, et al. Interpretation and inference in noninferiority randomized controlled trials in drug research. Clin Pharmacol Ther. 2010;88:420-3.
66. Cua YM, Kripalani S. Medication use in the transition from hospital to home. Ann Acad Med Singapore. 2008;37:136.
67. Halkin H, Shapiro J, Kurnik D, et al. Increased warfarin doses and decreased international normalized ratio response after nationwide generic switching. Clin Pharmacol Ther. 2003;74:215-21. (Pubitemid 37083097)
68. Lee HL, Kan CD, Yang YJ. Efficacy and tolerability of the switch from a branded to a generic warfarin sodium product: an observer-blinded, randomized, crossover study. Clin Ther. 2005;27:309-19.
69. Pereira JA, Holbrook AM, Dolovich L, et al. Are brand-name and generic warfarin interchangeable? Multiple n-of-1 randomized, crossover trials. Ann Pharmacother. 2005;39:1188-93. (Pubitemid 40943167)
70. Paterson JM, Mamdani M, Juurlink DN, et al. Clinical consequences of generic warfarin substitution: an ecological study. JAMA. 2006;296: 1969-72. (Pubitemid 44631442)
71. Arizona Center for Education and Research on Therapeutics. Drugs with possible risk of torsades de pointes. 2011. Available at: http://www.azcert. org/medical-pros/drug-lists/list-02.cfm?sort-Generic-name. Accessed April 10, 2011.
72. Planet Drugs Direct home page. 2011. Available at: http://www. planetdrugsdirect.com/. Accessed February 25, 2011.
73. U.S. Customs and Border Protection. Medication/drugs. 2011. Available at: http://www.cbp.gov/xp/cgov/travel/clearing/restricted/medication-drugs. xml. Accessed May 11, 2011.
74. U.S. Customs and Border Protection. FDA Enforcement Policy Regarding the Personal Importation of Violative Drugs. 2011. Available at: http://www. cbp.gov/xp/cgov/travel/clearing/restricted/medication-drugs.xml. Accessed May 19, 2011.
75. Beyth RJ, Shorr RI. Principles of drug therapy in older patients: rational drug prescribing. Clin Geriatr Med. 2002;18:577-92. (Pubitemid 34966694)
76. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255-64.
77. Kesselheim AS, Misono AS, Lee JL, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA. 2008;300:2514-26.
78. American Academy of Pediatrics Committee on Drugs: Generic prescribing, generic substitution, and therapeutic substitution. Pediatrics. 1987;79:835.
79. American Academy of Pediatrics. AAP publications retired and reaffirmed. Pediatrics. 2009;123:188.
80. Kwaku M, Altshuler J, Lu A. Tacrolimus pharmacokinetics and pharmacogenomics differences between adults and pediatric solid organ transplant recipients. Pharmaceutics. 2010;2:291-9.
81. Li JS, Eisenstein EL, Grabowski HG, et al. Economic return of clinical trials performed under the pediatric exclusivity program. JAMA. 2007; 297:480-8. (Pubitemid 46220803)
82. Leeder JS, Kearns GL. The challenges of delivering pharmacogenomics into clinical pediatrics. Pharmacogenomics J. 2002;2:141-3. (Pubitemid 34982219)
83. Children's National Medical Center Pharmacy and Therapeutics Committee. Therapeutic Interchange: Procedure CHPC: M:42p. Internal procedure in possession of Jeffrey Becker, M.D. 2011.
84. Schwartz JB. Gender-specific implications for cardiovascular medication use in the elderly optimizing therapy for older women. Cardiol Rev. 2003;11:275-98. (Pubitemid 37099656)
85. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 2002;347: 1403-11. (Pubitemid 35239712)
86. Adams KF Jr, Patterson JH, Gattis WA, et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the Digitalis Investigation Group trial: a retrospective analysis. J Am Coll Cardiol. 2005;46:497-504. (Pubitemid 41040292)
87. Ahmed A, Aban IB, Weaver MT, et al. Serum digoxin concentration and outcomes in women with heart failure: a bi-directional effect and a possible effect modification by ejection fraction. Eur J Heart Fail. 2006; 8:409-19. (Pubitemid 43842120)
88. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805-16. (Pubitemid 37509488)
89. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-304.
90. Pavek P, Ceckova M, Staud F. Variation of drug kinetics in pregnancy. Curr Drug Metab. 2009;10:520-9.
91. Koren G, Sakaguchi S, Klieger C, et al. Toward improved pregnancy labelling. J Popul Ther Clin Pharmacol. 2010;17:e349-57.
92. Jacobsen T, Sifontis N. Drug interactions and toxicities associated with the antiviral management of cytomegalovirus infection. Am J Health Syst Pharm. 2010;67:1417-25.
93. Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;120: 2271-306.
94. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction). Circulation. 2007;116:e148-e304.
95. Alexander KP, Chen AY, Roe MT, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA. 2005;294:3108-16. (Pubitemid 43016802)
96. Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non-ST- elevation myocardial infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;123:2022-60.
97. Nutescu EA, Lewis RK, Finley JM, et al. Hospital guidelines for use of low-molecular-weight heparins. Ann Pharmacother. 2003;37:1072-81. (Pubitemid 36875242)
98. Schneeweiss S, Maclure M, Dormuth CR, et al. A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences. Clin Pharmacol Ther. 2006;79:379-88.
99. Epilepsy Therapy Project. State laws or statutes governing generic substitution by pharmacists. 2011. Available at: http://professionals.epilepsy. com/page/statutes-by-pharmacists.html. Accessed February 1, 2010.